Reports Q3 revenue $141,000, consensus $60,000. As of September 30, 2023, Cardiff Oncology had approximately $81.4M in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the third quarter of 2023 was approximately $8M, an increase of approximately $0.5M from $7.5M for the same period in 2022. Based on its current expectations and projections, the company believes its current cash resources are sufficient to fund its operations into 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRDF:
- Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
- Cardiff Oncology announces results from trials in mPDAC and SCLC
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue